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Abstract
Purpose of Review This review investigated the use of perioperative non-steroidal anti-inflammatory drugs (NSAIDs) and long-term 
outcomes in cancer surgery patients, and whether this is dependent on cancer type, type of NSAID and timing of administration.
Findings Perioperative NSAID use was found to be associated with longer disease-free survival (hazard ration, HR = 0.84 
(95% CI, 0.73–0.97)) and overall survival (HR = 0.78 (95% CI, 0.64–0.94)). No difference was found between different 
types of NSAID for disease-free survival, although in overall survival ketorolac use was significant (HR = 0.63 (95% CI, 
0.42–0.95)). Analysis on the timing of NSAID administration found no subgroup to be associated with cancer outcomes. 
The cancer-type analysis found an association with outcomes in breast and ovarian cancers. However, the level of certainty 
remains very low, mostly due to the heterogeneity and the retrospective nature of most studies.
Summary Perioperative NSAID use may be associated with increased disease-free and overall survival after cancer surgery. 
This may be dependent on the type of cancer and type of NSAID, and further research is needed to support this. These data 
may inform future prospective trials, which are needed to determine the clinical impact, as well as optimal NSAID regimen.
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Introduction
Although surgical resection is a mainstay of curative cancer 
treatment, surgery has been identified as a high-risk time for 
cancer progression [1]. During surgery, an increased number 
of circulating tumour cells (CTCs) has the potential to travel 
to distant sites and form “micrometastases” [2]. This may be 
aided by increased vascularity, due to an increase in angio-
genic factors [3, 4], and immune suppression, mediated by 
pain and neural activation [5, 6]. Surgical stress also leads 
to local and systemic inflammation [1, 7]. This heightens 
the risk of recurrence, as environments rich in inflammatory 
molecules are more susceptible to colonisation by CTCs [8].
Preclinical and clinical studies have suggested that 
interventions given during the perioperative period greatly 
influence cancer recurrence and survival [9, 10]. This fragile 
period provides an opportunity to tip the balance between pro- 
and anti-metastatic signals and potentially determine whether 
cancer progresses or regresses [11, 12]. Non-steroidal anti-
inflammatory drugs (NSAIDs) are one method which could be 
utilised in the anaesthetic regimen to interrupt the surgical stress 
response. NSAIDs are known to inhibit the cyclooxygenase 
(COX) isoenzymes, which convert arachidonic acid to 
prostaglandins [13, 14]. Excess production of prostaglandin 
has been shown to be key in various oncological events [15].
Recent literature has evidenced that NSAIDs are ben-
eficial in cancer treatment and prevention [16–18]. Further 
studies have also shown that NSAIDs can reduce the produc-
tion of angiogenic factors [19–21]. However, the long-term 
use may negatively impact on protective COX mechanisms 
[22] so a short course of NSAIDs around the time of surgery 
may maximise benefit whilst limiting harm [1]. Importantly, 
animal studies have shown continuous and perioperative use 
of NSAIDs to reduce metastases by the same degree [23].
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A human study found that patients receiving a postoperative 
NSAID plus fentanyl had decreased serum concentrations of the 
inflammatory markers VEGF, TNF-α and IL-1β when compared 
to fentanyl alone [24]. However, these studies did not investigate 
survival outcomes, leaving the clinical benefit unclear. Even a 
small benefit could be significant due to the relatively safe nature 
and cost-effectiveness of the NSAID drug class [25].
This review and meta-analysis investigated the use of 
perioperative NSAIDs on cancer patients that underwent 
surgical intervention with intention to cure. It examined 
any association with disease-free survival (DFS) and over-
all survival (OS). A meta-analysis was conducted to fur-
ther investigate whether the type of cancer, type of NSAID 
and timing of administration influenced these associations. 
These important variables were investigated with the aim of 
identifying the right NSAID, the right patients and the right 
timing for optimum effect.
Methods
A systematic review was conducted in line with the proto-
cols established in the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) [26] and 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions version 6.1 [27]. Protocols were registered on the 
Prospero website on 05/02/21 detailing early search strat-
egy and eligibility criteria. Database searches were carried 
out on Ovid Medline (13/01/2021), Cochrane database 
(14/01/2021) and www.clinicaltrials.gov (14/01/2021) with 
an example search strategy available in Appendix 1.
Study Screening
Inclusion and exclusion criteria for the review were 
established according to the PICOS method (Population, 
Intervention, Comparison, Outcomes and Study design) 
suggested by the PRISMA guidelines: Population (P): 
cancer patients undergoing surgery with curative intent; 
Intervention (I): perioperative NSAIDs; Comparison (C): 
control patients that received no NSAIDS; Outcomes (O): 
long-term survival, cancer recurrence, overall survival; 
Study Design (S): human subjects, English language. 
Exclusion criteria included reviews, case reports, letters, 
ongoing trials, trials with no results, single-arm stud-
ies with no comparative group and short-term outcome 
measurement.
Rayyan QCRI software was used to export search results 
[28]. Two reviewers, independently screened titles and 
abstracts against eligibility criteria. Any conflicts during the 
process were discussed and resolved by a third party where 
agreement could not be reached.
Data Synthesis
Hazard ratios with 95% confidence intervals were extracted 
for DFS and OS outcomes and data were aggregated using the 
Cochrane RevMan5 software [29]. Subgroup analyses were 
also performed according to the predefined research questions. 
Sufficient data were available to compare types of NSAIDs 
used in the studies, cancer type and timing of administration. 
A narrative synthesis was performed for dose and duration.
Risk of Bias Analysis
Scottish Intercollegiate Guidelines Network (SIGN) check-
lists for cohort and randomised control trials [30] were 
used to assess the risk of bias within the included studies. 
Randomised control trials were further assessed using the 
Cochrane Risk of Bias tool. These were used to determine 
the potential for selection bias, detection bias and others. 
Finally, the GRADE classification system [27] was used to 
determine the likelihood that the interventions used were 
causally linked with the outcomes of focus.
Results
Search Results and Study Selection
The results of the search strategy are summarised in the 
PRISMA flow diagram in Figure 1. Ovid Medline search 
produced 255 studies; Cochrane database produced 52; 
and www.clinicaltrials.gov produced 84. Twenty studies 
were found to fit the eligibility criteria; however, no contact 
was received from authors of Lee et al. [31] regarding data 
needed, so the remaining 19 were included. Of these, 16 
provided sufficient data to be included in the meta-analysis.
During the screening process, there were thirteen conflicts 
between the two reviewers. These were resolved through 
discussion, and seven conflicts which could not be resolved 
were assessed by a third reviewer who made the final 
decision. The inter-rater variability test was performed and 
showed 96.5% concurrence between the two reviewers Fig. 2.
Study Characteristics
Data were extracted from 19 studies with a total of 12994 
participants. Study design and characteristics are summa-
rised in Table 1.
Risk of Bias
The risk of bias in each study is summarised in Appendix 2, 
with a later discussion of the risk of bias in each outcome.




All nineteen studies looked at long-term oncological out-
comes, as per the PICO criteria. Five studies stated “dis-
ease-free survival” as an outcome [32, 33, 34••, 35•, 36•] 
whilst a further one stated “progression-free survival” [37] 
and six “recurrence-free survival” [38–43]. Despite differing 
terms, these outcomes were sufficiently similar when defined 
in their respective studies to be considered in the overall 
DFS analysis. This included the three prostate cancer stud-
ies [44–46] for which biochemical recurrence-free survival 
was included in the DFS analysis, as PSA above 0.2 ng/ml 
was the apparent measure for recurrence. Two studies which 
looked at disease-specific survival [47, 48] and two which 
looked at distant recurrence were also included [49, 50•]. 
Regarding Forget et al. [40], data for RFS were extracted, 
except for the lung cancer centre where distant-metastasis-
free survival was used.
Hazard ratios for DFS were extracted from twenty cohorts 
and aggregated into a forest plot. Where the studies had 
calculated hazard ratios for subgroups as well as for overall 
NSAID vs. control comparison, overall use was extracted 
for this comparison. Some of the studies subcategorised data 
either by centre [40] or by type of NSAID used [39, 50•], 
and so these hazard ratios were extracted and included as 
separate cohorts in the final meta-analysis.
Thirteen cohorts reported a hazard ratio less than 1 which 
favoured the NSAID group compared to the non-NSAID 
group on disease-free survival. Seven of these cohorts had a 
statistically significant p value of less than 0.05. Seven cohorts 
had a hazard ratio of greater than 1 favouring the non-NSAID 
group; however, none of them was statistically significant.
Fig. 1  Flow diagram illustrating 
the number of studies included 
in each stage of the literature 
search. Adapted from PRISMA 
guidelines [26]
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OS
Twelve studies stated “overall survival” as an outcome [32, 33, 
34••, 35•, 37, 40–43, 45, 46] with one further study looking 
at 5-year mortality, defined as death by any cause, which 
was sufficiently similar [36•]. These were all included in the 
secondary outcome analysis. Hazard ratios were extracted 
from thirteen cohorts for OS and aggregated into a forest plot.
Nine cohorts reported a hazard ratio below 1 which 
favoured the NSAID group over the non-NSAID group in 
OS; however, only four of these values are statistically sig-
nificant with a p value of less than 0.05. Four cohorts had a 
hazard ratio of greater than 1 and none of these groups had 
a statistically significant p value.
Meta-analyses showed an association with both DFS 
and OS outcomes in the groups that received perioperative 
NSAIDs (Appendix Figures 3 and 4). However, heterogeneity 
was high, especially in DFS where I2 = 60%, indicating a sig-
nificant level of inconsistency between studies. Forest plots can 
be found in Appendix 3 and results are summarised in Table 2.
Three studies were not included in the meta-analysis, as 
they did not provide hazard ratios for DFS or OS. Their find-
ings are briefly summarised:
Cho et al. [49] found no association between NSAID use 
and DFS. Lee et al. [42] also found no statistically significant 
difference in DFS or OS between the NSAID group and con-
trol. Lönnroth et al. [48] found that disease-specific survival 
was 522 days ± 107 vs 313 ± 106 in the sham control group. 
No statistical analysis was performed on these numbers.
Cancer‑Type Subgroup
Data were aggregated into forest plots and stratified by cancer 
type, which can be found in Appendix 4. In DFS, heterogeneity 
was high in the breast cancer and lung cancer subgroups, with 
I2 = 77% and I2 = 57%, respectively. A statistically significant 
association with longer DFS was only seen in the breast cancer 
subgroup and ovarian cancer subgroup, although ovarian 
cancer had only one study so no aggregation was possible. For 
lung, colorectal and prostate cancer, aggregation detected no 
significant association between NSAID use and DFS. Bladder 
cancer and melanoma also had only one study each which 
meant that the aggregate was not applicable.
Seven of the cohorts did not report OS hazard ratio. In 
the OS analysis, NSAID use in none of the cancer types was 
significantly associated with OS. Heterogeneity was lower 
with breast cancer I2 = 41%, lung cancer I2 = 45%, and 
prostate cancer I2 = 40%, although the number of included 
studies was also lower. Ovarian, tongue and kidney cancer 





































































































































































































































































































































































































































































146   Page 6 of 20 Current Oncology Reports (2021) 23: 146
1 3
Type of NSAID Subgroup
Two studies found an association with better cancer outcomes 
in perioperative ketorolac use, but not in diclofenac use [39, 
50•]. Choi et al. [38] also found perioperative ketorolac use 
to be an independent predictor of OS in early-stage lung can-
cer, but not ibuprofen or celecoxib. However, a prospective 
randomised control trial looking at ketorolac use found no 
statistical difference in DFS or OS when compared to patients 
who had not received ketorolac [34••]. Meta-analysis was per-
formed to look at the effects of each drug type across studies.
Eleven studies which investigated a single type of NSAID, 
or disaggregated data for individual types of NSAID, gave 
hazard ratios for DFS and were included in a forest plot for 
DFS [36•, 39–41, 43–47, 50•]. Six also calculated hazard 
ratios for OS for their respective NSAID and were therefore 
included in secondary outcome analysis [34••, 36•, 40, 43, 
45, 46]. Forest plots can be found in Appendix 5.
The remaining studies grouped patients who had received 
multiple types of NSAIDs and consequently could not be 
used in this meta-analysis.
For the primary outcome, DFS, all NSAID-type subgroups 
crossed the line of no effect. This means there was no 
statistically significant difference between NSAID and control. 
Heterogeneity remained high in this subgroup analysis, with 
I2 = 59% in the ketorolac studies. Overall, the hazard ratios 
which most favour the NSAID were seen in ketorolac, although 
the association was not found to be statistically significant.
For the secondary outcome, OS, the only type of NSAID 
found to have a statistical effect in comparison with control was 
ketorolac (HR = 0.63 (95% CI, 0.42–0.95)). Heterogeneity was 
lower in the ketorolac studies in the OS analysis, with I2 = 28%, 
but the number of studies included was also lower. Heterogeneity 
remained high in the diclofenac studies with I2 = 58%.
Timing
Goh et al. [41] found that preoperative aspirin users had 
worse RFS, whereas the risk of recurrence and death in 
postoperative aspirin users was approximately 60% lower 
compared to patients who had not used postoperative aspirin. 
Forget et al. [39] found an association between intraopera-
tive NSAID use and improved DFS, but not postoperative, 
although different drugs were used at each time point.
Meta-analysis was performed to compare time points. 
Studies were excluded from this subgroup analysis that were 
not specific about timings or which grouped patients who 
received NSAIDs at multiple time points.
For DFS, fourteen studies reported hazard ratios [32–34••, 
36•, 37–40, 43–46]. Only one study provided sufficient data 
for inclusion in the preoperative use subgroup [41]. For OS, 
no studies had calculated hazard ratios for preoperative use, so 
this subgroup could not be included in the secondary outcome 
analysis. However, five could be included in the intraoperative 
subgroup [32–34••, 40, 43] and five in the postoperative 
subgroup [36•, 37, 38, 45, 46]. Both data sets were pooled in 
forest plots, which can be found in Appendix 6.
For both DFS and OS, there was no difference detected 
between intervention and control for either intraoperative 
or postoperative NSAID subgroups. Preoperative use was 
associated with a worsened DFS in the single study which 
was included in this analysis. A larger degree of heterogene-
ity was seen in the data from intraoperative studies, with I2 
= 53% compared to I2 = 35% in the DFS analysis.
Dose and Duration
In studies which used ketorolac, eight included participants 
who had been given a single dose [33, 34••, 39, 40, 44, 47, 
50•]. Only the prospective trials were able to be specific 
about dose, with Cho et al. [49] giving 60 mg and Forget 
et al. [34••] giving 30 mg. The rest were retrospective and so 
included patients whose doses varied depending on patient 
factors such as weight and creatinine clearance. This meant 
that a comparison of dosage was not plausible. Three stud-
ies looked at multiple doses of ketorolac [42, 45, 46]. None 
of these found a statistically significant difference between 
NSAID and control use.
Table 2  Overall effect estimates for each outcome in the comparison between perioperative NSAID use and no perioperative NSAID use 









Certainty of the evidence (GRADE) Comments
Disease-free survival 0.84 0.73–0.97 11075 [16] Low ⊕⊕⊝⊝
Due to the risk of bias in studies, high 
heterogeneity, and imprecise definitions
Perioperative NSAIDs 
may be associated with 
increased disease-free 
survival.
Overall survival 0.78 0.64–0.94 6954 [11] Low ⊕⊕⊝⊝
Due to the risk of bias in studies
Perioperative NSAIDs 
may be associated 
with increased overall 
survival.
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In diclofenac, three studies used a single intraoperative 
dose of 75 mg [33, 40, 50•]. Desmedt et al. [50•] found no 
association with DFS and Forget et al. [40] found a positive 
association with DFS in their lung cancer cohort. The third 
study did not disaggregate data for diclofenac so conclusions 
could not be drawn. A further two studies included multiple 
doses [36•, 39]. Neither study found an association with the 
cancer outcomes investigated by this review.
The remaining NSAIDs used were not comparable in 
terms of dose and duration because doses or timings were not 




The current review looked at 12,994 participants who were 
treated perioperatively with NSAIDs. Meta-analysis showed an 
association between perioperative NSAID use and longer DFS 
and OS. This suggests that a short course of NSAIDs in the perio-
perative period may be beneficial for cancer surgery patients. 
However, there is a considerable amount of heterogeneity 
between the studies, and most trials were based on retrospective 
data, indicating that this association could be due to other factors.
Cancer-Type Subgroup
The average HR of all breast cancer studies indicated that 
NSAIDs given to breast cancer patients may reduce the risk 
of disease recurrence by 42%. However, the heterogeneity 
was very high. A strength of this subgroup analysis was that 
this type of cancer had the most studies and data recorded 
which improved precision. This analysis had a low heteroge-
neity score which added confidence to the result.
The average HR of DFS for lung cancer is optimistic as 
this analysis detected a 31% chance of reduction in disease 
recurrence. However, wide confidence intervals and the important 
heterogeneity preclude any definitive conclusion. There were only 
three study data available which was also a limitation.
The average HR for DFS in colorectal cancer indicated 
that there was no difference between NSAIDs and non-
NSAIDs group. Zero percent heterogeneity between the 
studies added strength to the aggregate value. Three out of 
the four cohorts were from the same study which possibly 
reduces the reliability of the result.
There was no effect observed for prostate cancer patients. 
More studies investigating this effect should be conducted 
to corroborate this no effect, as COX 2 is overproduced in 
prostate cancer cells, and studies have shown that COX2 
inhibitors can induce apoptosis in prostate cancer cell lines 
[51–53]. Another weakness in the analysis of the result is 
that Forget et al. [44] had a relatively short follow-up period 
with a mean of 38 months. Therefore, these results could be 
different with a longer follow-up, as prostate cancer patients 
live for many years after diagnosis which can make interpre-
tation of survival outcomes problematic.
The association between perioperative NSAID use and 
longer DFS in breast cancer surgery is consistent with many 
of the breast cancer studies which is reassuring for clini-
cians and patients. In contrast, other cancer types such as 
prostate, colorectal, bladder and melanoma did not appear 
to be affected. This could imply that the effect of NSAIDS is 
tumour specific, with host immune responses being altered 
differently by NSAID mechanisms in different cancer types.
Since only one study investigated bladder cancer, ovarian can-
cer and melanoma, firm conclusions are difficult to draw. However, 
the results do suggest that there was a benefit in bladder cancer and 
ovarian cancer. This indicates a demand for more observational 
studies or prospective studies in these less common cancers.
Type of NSAID Subgroup
Meta-analysis indicated that ketorolac may have the greatest 
effect on oncological outcomes. However, if the association 
between ketorolac and improved OS was due to the proposed 
anticancer effects of NSAIDs, then it would be expected that 
this would also affect DFS, which, in this analysis, was not 
seen.
On balance, fewer studies reported OS, which could have 
underpowered the analysis and may therefore account for the 
different results. This discrepancy could also be explained 
by the retrospective designs of many of the included studies. 
Retrospective cohort studies were more likely to have dif-
fering participant characteristics between intervention and 
control groups, so there may have been confounding factors 
which affected OS but not DFS in some of the studies. For 
example, several studies noted that younger patients were 
more likely to receive NSAIDs [32, 33]. This means that a 
detected OS benefit could be age related rather than inter-
vention related. Additionally, only one study was included 
for each of parecoxib, aspirin and ibuprofen, affecting cer-
tainty regarding the accuracy of these results.
For these reasons, it cannot be definitively concluded that 
any particular NSAID is superior in effect on oncological 
outcomes. Nevertheless, the trends identified by this analysis 
may be useful in the design of future studies. Ketorolac could be 
the NSAID most likely to give favourable outcomes and would 
therefore be a good candidate for future prospective trials.
Timing of NSAID Subgroup
No statistical effect was detected for intraoperative or post-
operative NSAID subgroups. Preoperative NSAID use was 
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found to negatively impact on survival outcomes; however, 
only one study provided hazard ratios for preoperative use, 
so this result was underpowered.
This subgroup analysis was limited by varying definitions of 
the terms “intraoperative” and “postoperative”. For intraoperative 
studies, all were included that stated “intraoperative” as the 
timing of administration. Yet, some were specific to induction 
of anaesthesia, some were given pre-incision and others were 
given prior to surgical closure. These studies were grouped 
together for the purposes of this meta-analysis as per the protocol. 
In the “postoperative” subgroup, some studies gave a single 
postoperative dose, others multiple doses within 72 h and others 
included patients who received NSAIDs for longer. For example, 
Schack et al. [36•] included NSAID use of at least 2 days within 
the first 7 days after surgery. As NSAIDs are thought to inhibit 
surgery-induced inflammation, some of these NSAIDs may have 
been administered too late to have any impact on outcomes. 
Consequently, some of these specific time points may be superior 
to others, but this analysis would have been unable to detect this.
Dose and Duration
Due to inconsistency between studies, it was difficult for this 
review to draw conclusions on optimal dose or duration. In 
ketorolac use, more favourable outcomes were seen in studies 
which looked at a single dose rather than multiple doses, where 
no effect was seen. However, the timings of these doses could 
be responsible for this trend, rather than dosage, as single doses 
were all intraoperative and multiple doses all postoperative. 
Dosage also appeared to be dependent on patient factors such 
as weight and renal function. Further research will be required 
to identify any dose-dependent difference in outcomes.
Review Strengths and Limitations
This is the most updated systematic review exploring 
whether perioperative NSAIDs can improve DFS and OS 
for cancer patients. This review was strengthened by the 
protocol which was registered with Prospero prior to formal 
searching. Searching multiple databases attempted to ensure 
no relevant studies were missed. Predefined PICO criteria 
reduced the risk of bias in study selection as did the use of 
two team members independently screening and appraising 
the studies. This is an independent systematic review with 
no conflicts of interest minimising additional bias.
Fifteen studies were retrospective which carry an inherent 
risk of selection bias due to the absence of randomisation. 
Furthermore, pooling data from observational retrospective 
studies put the results at a risk of residual confounding. Some 
studies did not report certain confounding variables such as 
BMI status and smoking status. These are crucial factors that 
could have affected OS and DFS. The high heterogeneity 
can also create management when interpreting the results. In 
addition, not all studies reported complete data required for 
analysis. This could also have introduced a risk of publication 
bias if the unpublished data were not favourable towards the 
intervention and consequently not reported. The fact that most 
studies included multivariate adjustments reduced the effect of 
residual confounding and adds more confidence in the results.
These studies could also carry a risk of detection bias, as 
follow-up and outcome measurement cannot be predefined in a 
retrospective study. However, this was minimised as survival out-
comes were largely objective. Many centres also used published 
methods or validated algorithms for detecting recurrence or dis-
tant metastases, strengthening the consistency between studies.
Aggregating data for outcomes which varied in definition 
was a limitation of this review. DFS takes into account distant 
metastases, locoregional recurrence and disease-specific survival, 
whereas some included studies only took one or two of these fac-
tors into account in their definitions. Others looked at each of these 
factors separately. These outcome definitions may have masked 
true effects across studies; however, definitions were sufficiently 
similar to identify overall trends which could inform future trials.
Further Considerations
Some included studies also looked at the use of NSAIDs 
specifically in patients who had high levels of inflammatory 
markers. This is rational as these patients are more at risk of 
dormant tumour cells being activated due to environments 
rich in inflammatory cells. Huang et al. [35•] did not find 
a significant association between perioperative NSAID use 
and DFS overall, but did find a significant association in a 
subset of patients with high PLR. Two studies also found 
that high NLR levels were an independent predictor of poor 
survival [33, 40], highlighting the potential importance of 
these inflammatory markers. Targeting perioperative NSAID 
therapy to these particular subgroups may be an important 
development in cancer surgical outcomes.
Conclusion
Surgical stress may increase the risk of postoperative cancer 
recurrence or metastases. Anaesthetic interventions may have 
a role in preventing this process to improve oncological out-
comes. NSAIDs may be an important factor, as this review has 
found an association between perioperative NSAID use and 
longer DFS and OS. This review has also given clues as to the 
right cancer type, the right drug and the right timing for admin-
istration in order to maximise this effect. Even a small benefit 
may be significant due to the safety profile and cost-effective-
ness of this class of drugs. However, more prospective trials are 
required to confirm the best anti-inflammatory regimen.
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Appendix 1
Fig. 2  Search Strategy Example - Cochrane Database, searched 14/01/2021
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Appendix 2
 Tables 3 and 4
Table 3  Risk of bias in included cohort studies. Risk according to SIGN guideline methodology assessment for cohort studies, with comments 
on potential sources of bias within each study. Retrospective studies could not be graded higher than “acceptable” according to SIGN guidelines
Forget 2011 (+) 
Acceptable 
Retrospective design with risk of selection bias. Unknown postoperative analgesic use 
which may have affected results. Multivariate analysis and consistent, objective follow-up 
for outcome measured. 
Forget 2013 (+) 
Acceptable 
Retrospective design with risk of selection bias. Multiple centres with multiple cancer types. 
Multivariate analysis where possible takes into account potential confounders. 
Forget 2014 (+) 
Acceptable 
Risk of selection bias due to retrospective design. Consistent in surgeon and follow-up and 
takes into account potential confounders in multivariate analysis. 
Goh 2014 (+) 
Acceptable 
Risk of selection bias due to retrospective analysis and inability to identify patients 
prescribed aspirin by general practitioners. However, uses high quality data and multivariate 
analysis to reduce effects of potential confounders. 
Guo 2015 (+) 
Acceptable 
Retrospective so some risk of selection and detection bias, but confounders taken into 
account in adjusted analysis. 
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Table 3  (continued)
Table 4  Risk of bias in included randomised control trials. Risk according to SIGN guideline methodology assessment for randomised control 
trials, and Cochrane risk of bias tool, with comments on potential sources of bias within each study
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Appendix 3







Fig. 3  Comparison of disease-
free survival in any periopera-
tive NSAID use vs. no perio-
perative NSAID use. Studies 
included are those that provided 
hazard ratios for disease-free 
survival, with 95% confidence 
intervals. Desmedt 2018a = 
ketorolac; Desmedt 2018b 
= diclofenac; Forget 2010a 
= diclofenac; Forget 2010b 
= ketorolac; Forget 2013a = 
breast centre 1; Forget 2013b = 
breast centre 2; Forget 2013d 
=lung centre.
Fig. 4  Comparison of overall survival in perioperative NSAID use vs. 
no perioperative NSAID use. Studies included are those that provided 
hazard ratios for overall survival, with 95% confidence intervals. For-
get 2013a = breast centre 1; Forget 2013b = breast centre 2; Forget 
2013d =lung centre
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Fig. 5  shows DFS stratified by type of cancer. Desmedt 2018a = 
ketorolac; Desmedt 2018b = diclofenac; Forget 2010a = diclofenac; 
Forget 2010b = ketorolac; Forget 2013a = breast centre 1; Forget 
2013b = breast centre 2; Forget 2013d = lung centre; Schack 2019a 
= diclofenac; Schack 2019b = ibuprofen; Schack 2019c = overall 
NSAID group.
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Fig. 6  shows OS stratified by type of cancer. Desmedt 2018a = ketorolac; Forget 2013a = breast centre 1; Forget 2013b = breast centre 2; Forget 
2013d = lung centre; Schack 2019c = overall NSAID group.
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Appendix 5
Type of NSAID Subgroup Analysis
 Fig. 7
 Fig. 8
Fig. 7  Comparison of disease-free survival in perioperative NSAID 
use vs. no perioperative NSAID use, grouped by type of NSAID 
given. Studies included are those that provided hazard ratios for 
disease-free survival, with 95% confidence intervals, in a specific 
named NSAID drug. Desmedt 2018a = ketorolac; Desmedt 2018b 
= diclofenac; Forget 2010a = diclofenac; Forget 2010b = ketorolac; 
Forget 2013b = breast centre 2; Forget 2013d = lung centre; Schack 
2019a = diclofenac; Schack 2019b = ibuprofen
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Appendix 6
Timing of NSAID Administration Subgroup Analysis
 Fig. 9
 Fig. 10
Fig. 8  Comparison of over-
all survival in perioperative 
NSAID use vs. no perioperative 
NSAID use, stratified by type 
of NSAID. Studies included 
are those that provided hazard 
ratios for overall survival, with 
95% confidence intervals, in a 
specific named NSAID type. 
Forget 2013b = breast centre 
2; Forget 2013d = lung centre; 
Schack 2019a = diclofenac; 
Schack 2019b = ibuprofen
Fig. 9  Comparison of disease-
free survival in NSAID use 
vs. no NSAID use, grouped by 
the timing of NSAID admin-
istration. Studies are grouped 
to compare intraoperative, 
postoperative, and preoperative 
use. Studies included are those 
that provided hazard ratios for 
disease-free survival, with 95% 
confidence intervals, and gave 
NSAIDs at specific time points 
only, or investigated specific 
time point subgroups. Desmedt 
2018a = ketorolac; Desmedt 
2018b = diclofenac; Forget 
2010a = diclofenac; Forget 
2010b = ketorolac; Forget 
2013d = lung centre; Schack 
2019a = diclofenac; Schack 
2019b = ibuprofen
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